-
-
-
-
-
-
-
Alkermes (ALKS) Tops Q1 EPS by 14c; offers guidance
-
-
-
-
-
-
-
Alkermes (ALKS) PT Raised to $47 at UBS
-
-
-
-
-
-
-
Mizuho on Alkermes (ALKS): 'See Attactive Buying Opportunity'
-
-
-
-
-
-
-
Truist Securities Comments on Centessa Pharmaceuticals (CNTA) Amid 18pct Drop
-
-
-
-
-
-
-
RBC Capital on Jazz Pharmaceuticals (JAZZ): 'we would be buyers on the potential upcoming positive ph.III zanidatimab data in GEA'
-
-
-
-
-
-
-
RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
-
-
-
-
-
-
-
Alkermes (ALKS) Tops Q2 EPS by 16c
-
416,544 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

